Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

24432 ARTÍCULOS , VIENDO DEL 4786 AL 4800

Effects of Linkers and Substitutions on Multitarget Directed Ligands for Alzheimer's Diseases: Emerging Paradigms and Strategies

Pravin N, Jozwiak K.

Int J Mol Sci. 2022 May 29;23(11):6085. doi: 10.3390/ijms23116085.

Rlip76: An Unexplored Player in Neurodegeneration and Alzheimer's Disease?

Hindle A, Singh SP, Pradeepkiran JA, Bose C, Vijayan M, Kshirsagar S, Sawant NA, Reddy PH.

Int J Mol Sci. 2022 May 29;23(11):6098. doi: 10.3390/ijms23116098.

Noradrenaline in Alzheimer's Disease: A New Potential Therapeutic Target

Gutiérrez IL, Dello Russo C, Novellino F, Caso JR, García-Bueno B, Leza JC, Madrigal JLM.

Int J Mol Sci. 2022 May 30;23(11):6143. doi: 10.3390/ijms23116143.

Synapse pathology in Alzheimer's disease

Griffiths J, Grant SGN.

Semin Cell Dev Biol. 2023 Apr;139:13-23. doi: 10.1016/j.semcdb.2022.05.028. Epub 2022 Jun 9.

How neurons die in Alzheimer's disease: Implications for neuroinflammation

Mangalmurti A, Lukens JR.

Curr Opin Neurobiol. 2022 Aug;75:102575. doi: 10.1016/j.conb.2022.102575. Epub 2022 Jun 10.

Ameliorative Effects of Phytomedicines on Alzheimer's Patients

Khandia R, Viswanathan N, Singhal S, Alqahtani T, Almikhlafi MA, Simonov AN, Ashraf GM.

Curr Alzheimer Res. 2022;19(6):420-439. doi: 10.2174/1567205019666220610155608.

Microglia in Alzheimer's Disease: A Favorable Cellular Target to Ameliorate Alzheimer's Pathogenesis

Sumsuzzman DM, Uddin MS, Kabir MT, Hasana S, Perveen A, Alanazi IS, Albadrani GM, Abdel-Daim MM, Ashraf GM.

Mediators Inflamm. 2022 Jun 2;2022:6052932. doi: 10.1155/2022/6052932. eCollection 2022.

Effects of Tianeptine Treatment on Depression and Cognitive Function in Patients with Alzheimer's Disease: A 12-Month Retrospective Observational Study

García-Alberca JM, Gris E, de la Guía P, Mendoza S.

J Alzheimers Dis. 2022;88(2):707-720. doi: 10.3233/JAD-215630.

Safety and Efficacy of Semorinemab in Individuals With Prodromal to Mild Alzheimer Disease: A Randomized Clinical Trial

Teng E, Manser PT, Pickthorn K, Brunstein F, Blendstrup M, Sanabria Bohorquez S, Wildsmith KR, Toth B, Dolton M, Ramakrishnan V, Bobbala A, Sikkes SAM, Ward M, Fuji RN, Kerchner GA; Tauriel Investigators.

JAMA Neurol. 2022 Aug 1;79(8):758-767. doi: 10.1001/jamaneurol.2022.1375.

Deep brain stimulation of fornix for memory improvement in Alzheimer's disease: A critical review

Li R, Zhang C, Rao Y, Yuan TF.

Ageing Res Rev. 2022 Aug;79:101668. doi: 10.1016/j.arr.2022.101668. Epub 2022 Jun 12.

Cathepsin B Gene Knockout Improves Behavioral Deficits and Reduces Pathology in Models of Neurologic Disorders

Hook G, Reinheckel T, Ni J, Wu Z, Kindy M, Peters C, Hook V.

Pharmacol Rev. 2022 Jul;74(3):600-629. doi: 10.1124/pharmrev.121.000527.

Promising application of polyoxometalates in the treatment of cancer, infectious diseases and Alzheimer's disease

Wang X, Wei S, Zhao C, Li X, Jin J, Shi X, Su Z, Li J, Wang J.

J Biol Inorg Chem. 2022 Aug;27(4-5):405-419. doi: 10.1007/s00775-022-01942-7. Epub 2022 Jun 17.

Rational drug design strategies for the development of promising multi-target directed indole hybrids as Anti-Alzheimer agents

George N, Jawaid Akhtar M, Al Balushi KA, Alam Khan S.

Bioorg Chem. 2022 Oct;127:105941. doi: 10.1016/j.bioorg.2022.105941. Epub 2022 Jun 10.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias